Litchfield Hills analyst Theodore O'Neill initiated coverage of Silexion Therapeutics with a Buy rating and $6 price target. Silexion Therapeutics is targeting unmet need in KRAS-driven cancers and its siRNA platform takes a fundamentally different approach from current KRAS-targeted therapies, the analyst tells investors. The company is positioned to enter late-stage clinical development, with regulatory submission to the Israel Ministry of Health in Q4 followed by filings in Germany and the broader European Union in Q1, the analyst noted.
